| pepinemab (VX15) / Vaccinex |
NCT05102721: Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1b/2 | 48 | US | Avelumab and Pepinemab | Vaccinex Inc., University of Rochester | Metastatic Pancreatic Adenocarcinoma | 12/28 | 12/28 | | |
NCT03320330: Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 26 | US | Laboratory Biomarker Analysis, Pepinemab, moAb VX15/2503, VX15/2503, Pharmacological Study | Children's Oncology Group, National Cancer Institute (NCI) | Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma | 12/20 | 09/24 | | |
NCT03205644: VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 75 | US | Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Laboratory Biomarker Analysis, Pharmacological Study | Children's Oncology Group, National Cancer Institute (NCI), COG Phase I Consortium | Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm | 09/21 | 10/21 | | |
| Active, not recruiting | 1/2 | 50 | US | Pepinemab, Placebo | Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association | Alzheimer Disease | 06/23 | 06/24 | | |
KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
|
|
| Recruiting | 1/2 | 65 | US | pepinemab + pembrolizumab, KEYTRUDA® | Vaccinex Inc., Merck Sharp & Dohme LLC | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | 12/24 | 12/24 | | |
|
